Literature DB >> 31026728

Analysis of pharmacological mechanisms and targets mining of Wuzi-Yanzong-Wan for treating non-obstructive oligoasthenospermia.

Dixin Zou1, Xuedan Meng2, Baoli Wang3, Yihang Dai4, Ranran Yang5, Yaran Suo6, Yiqing Wu7, Weipeng Yang8, Ruichao Lin9.   

Abstract

As a classical traditional Chinese medicine, Wuzi-Yanzong-Wan (WZYZW) has been widely applied for several centuries to treat non-obstructive oligoasthenozoospermia (NOA), although its pharmacological mechanisms remain largely unknown. In this study, both plasma and urine metabolomics profiling was first analysed to explore the therapeutic mechanisms of WZYZW in NOA rats induced by removal of the unilateral testicle. Then, 106 identified compounds comprising WZYZW (our previous work), for which putative targets were discovered using systems pharmacology, were systematically analysed via mRNA microarrays to validate their putative targets. Finally, metabolomics-tested WZYZW-regulated metabolites were connected with validated targets using Spearman correlation analysis to further confirm the targets from a biological perspective. The results suggested that WZYZW plays key roles in modulating the concentrations of 18 metabolites in the metabolism of amino acids, lipids and so on, normalizing the metabolic phenotype and regulating metabolic disorders. Moreover, 27 targets of WZYZW (23 compounds) against NOA were validated, and metabolomics-tested metabolites were also found to be significantly related to these identified targets, suggesting that these targets and compounds are worthy of further research. This work offers the first systematic investigation of the efficacy of WZYZW against NOA and illustrates a practicable approach for explaining the molecular mechanisms of multicomponent drugs.
Copyright © 2019 The Authors. Published by Elsevier Masson SAS.. All rights reserved.

Entities:  

Keywords:  Metabonomics; Molecular mechanism; Non-obstructive oligoasthenozoospermia; Systems pharmacology; Wuzi-Yanzong-Wan

Year:  2019        PMID: 31026728     DOI: 10.1016/j.biopha.2019.108898

Source DB:  PubMed          Journal:  Biomed Pharmacother        ISSN: 0753-3322            Impact factor:   6.529


  4 in total

1.  Metabolomic profiling and alleviation of oxidative stress of Huangjing Zanyu capsule treating oligoasthenospermia.

Authors:  Boyi Li; Jinchen Ma; Linghui Zhu; Yun Yan; Yuqi Wu; Chenglong Zheng; Zhisheng Wu; Lingru Li; Qi Wang; Yanfei Zheng
Journal:  Transl Androl Urol       Date:  2022-05

2.  Establishment of an oligoasthenospermia mouse model based on TAp73 gene suppression.

Authors:  Hong-Juan Liu; Meng-Yun Deng; Yan-Yan Zhu; De-Ling Wu; Xiao-Hui Tong; Li Li; Lei Wang; Fei Xu; Tong-Sheng Wang
Journal:  Animal Model Exp Med       Date:  2021-11-09

3.  Effect of Wuzi Yanzong prescription on oligoasthenozoospermia rats based on UPLC-Q-TOF-MS metabolomics.

Authors:  Zhimin Chen; Baohua Dong; Yunxiu Jiang; Ying Peng; Wenbing Li; Lingying Yu; Yongxiang Gao; Changjiang Hu
Journal:  Pharm Biol       Date:  2022-12       Impact factor: 3.889

4.  The Efficacy and Safety of the Zhuyun Formula and Auricular Acupressure for the Infertile Women with Recurrent Implantation Failure: A Randomized Controlled Trial.

Authors:  Hang Zhou; Xiaoyan Zheng; Wanting Xia; Qianhong Ma; Jinmei Li; Qian Zeng; Jinzhu Huang
Journal:  Evid Based Complement Alternat Med       Date:  2022-10-11       Impact factor: 2.650

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.